TRUST study data confirms safety and efficacy of erlotinib for advanced lung cancer

	Tweet

Featured in the October edition of the Journal of Thoracic Oncology (JTO), data from The Tarceva Lung Cancer Survival Treatment (TRUST) confirms the safety and efficacy profile of erlotinib, a highly potent oral active, reversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine-kinase (TK) activity in a large heterogeneous non-small cell lung cancer (NSCLC) population.

Erlotinib has been shown to significantly increase survival for patients with previously treated advanced NSCLC. Certain groups of patients with NSCLC, such as those with a particular type of cancer - adenocarcinoma , women, Asian ethnicity and non (minimal) smokers are reported to be more likely to have tumor responses to EGFR TK inhibitors (TKIs) than other groups. However, results from the TRUST study suggest that erlotinib can benefit a wide range of patients, including those who have previously been thought unlikely to benefit from this treatment.

The large, global, open-labeled, phase IV trial TRUST study included the participation of 513 centers across 51 countries, culminating safety data from more than 6,500 patients.

In patients with advanced NSCLC, the progression-free survival and overall survival in this study were 3.25 months and 7.9 months, respectively, and the disease control rate (defined as the sum complete response, partial response, or stable disease) was 69 percent.

As a post marketing surveillance trial (phase IV) occurring after erlotinib received permission to be sold, the study provided an opportunity to evaluate the efficacy and safety of this medication in a broad patient population in a real-life clinical setting. Furthermore, it included patients with advanced stage IIIB/IV NSCLC who had previously failed on or were considered unsuitable to receive standard chemotherapy or radiotherapy and were ineligible for other erlotinib trials.

“The criteria used for selecting the most appropriate therapy for a patient are of particular interest to physicians,” explains lead investigator Martin Reck, MD, PhD. “Tumors with EGFR mutations have been shown to be highly responsive to EGFR TKIs. Although patients whose tumors have these mutations are likely to obtain a greater magnitude of benefit from EGFR TKIs such as erlotinib, it is important to note that the absence of these mutations does not necessarily result in a lack of benefit with erlotinib therapy.”

###

Journal of Thoracic Oncology (JTO)

The JTO is a prized resource for medical specialists and scientists who focus on the detection, prevention, diagnosis and treatment of lung cancer. The JTO is the official monthly journal of the International Association for the Study of Lung Cancer (IASLC.org) and emphasizes a multidisciplinary approach, including original research (clinical trials and translational or basic research), reviews and opinion pieces.

###

Contact: Kaitlin Doody

202-587-2553
International Association for the Study of Lung Cancer

RELATED STORIES:
Non-Surgical Treatment Gives Lung Cancer Patients Three Years or More   New lung cancer staging system revealed   Who should get screened for lung cancer?   Secondhand smoke exposure in childhood increases lung cancer risk later in life   CT screening can identify curable lung cancers   New technique detects specific chromosomal damage, may indicate lung cancer risk   Long-term cannabis use raises risk of lung cancer   Ovary removal may increase lung cancer risk   Lung Cancer: Treatment of Non-Small Cell Lung Cancer in the Elderly   Researchers Identify Tumor-Suppressor Gene for Lung Cancer   Clinical insight improves treatment with new lung cancer drug   Tooth Loss Linked to Esophageal, Head and Neck, and Lung Cancer   Researchers Identify Specific Lung Cancer Susceptibility Gene   Gene combination increases risk of lung cancer, particularly in light smokers, CAMH study finds   Cancer immunotherapy shows long-term promise in lung cancer   New lung cancer drug shows dramatic results for shrinking tumors   BATTLE Links Potential Biomarkers to Drugs for Lung Cancer   Lung cancer risk increases with expression of specific genes   WHO starts drive against environmental cancer risk   New test predicts if lung cancer will spread   An “HIV-test” Equivalent for the Early Detection of Lung Cancer   Array shares rise on lung cancer, melanoma results

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]